Article ; Online: Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.
Journal of medicinal chemistry
2022 Volume 65, Issue 13, Page(s) 8686–8698
Abstract: The U.S. FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an inhibitor of the main protease ( ... ...
Abstract | The U.S. FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an inhibitor of the main protease (M |
---|---|
MeSH term(s) | Coronavirus 3C Proteases ; Humans ; Pandemics ; SARS-CoV-2/genetics ; Viral Nonstructural Proteins/chemistry ; COVID-19 Drug Treatment |
Chemical Substances | Viral Nonstructural Proteins ; Coronavirus 3C Proteases (EC 3.4.22.28) |
Language | English |
Publishing date | 2022-06-22 |
Publishing country | United States |
Document type | Journal Article ; Review ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural |
ZDB-ID | 218133-2 |
ISSN | 1520-4804 ; 0022-2623 |
ISSN (online) | 1520-4804 |
ISSN | 0022-2623 |
DOI | 10.1021/acs.jmedchem.2c00404 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.B 151: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MB 1: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.